Author's response to reviews

Title: Influence of Serous Retinal Detachment on Macular Sensitivity and Morphology After Intravitreal Triamcinolone Acetonide For Macular Edema With Branch Retinal Vein Occlusion: a case series

Authors:

Hidetaka Noma (nomahide@tymc.twmu.ac.jp)
Hideharu Funatsu (hfunatsu@tymc.twmu.ac.jp)
Tatsuya Mimura (mimurat-tky@umin.ac.jp)
Katsunori Shimada (kshimada@statz.co.jp)

Version: 3 Date: 5 March 2012

Author's response to reviews: see over
March 5, 2012

Editor-in-Chief: Dr. Jigisha Patel
BMC Ophthalmology, BioMed Central Ltd

Title: Influence of Serous Retinal Detachment on Macular Sensitivity and Morphology After Intravitreal Triamcinolone Acetonide For Macular Edema With Branch Retinal Vein Occlusion: a case series.

Dear Dr. Patel:

Thank you very much for your e-mail of February 23, 2012 and for your helpful and constructive comments about our manuscript (MS: 3891279356540496R2) entitled “Influence of Serous Retinal Detachment on Macular Sensitivity and Morphology After Intravitreal Triamcinolone Acetonide For Macular Edema With Branch Retinal Vein Occlusion: a case series.” According to the reviewers’ comments, we have revised our manuscript as described on the following pages.

We hope that the revised manuscript adequately addresses your concerns and those of the reviewers, and that our manuscript will now be considered acceptable for publication in your excellent journal.

Sincerely yours,

Hidetaka Noma

Hidetaka Noma, M.D.
Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women’s Medical University, 477-96, Owada-shinden, Yachiyo, Chiba 276-8524, Japan; E-mail: nomahide@tymc.twmu.ac.jp, Tel: +81-47-450-6000, Fax: +81-47-458-7047
Comments and responses

Comment 1: Thank you for your response, however the wording in your manuscript is not entirely clear. I would be most grateful if could you let us know whether the patients included in this study would have been treated with triamcinolone whether or not they were included in this study and whether you use this treatment generally at your hospital.

Answer:
Thank you for this helpful comment. At our hospital, we have several treatment options, including follow-up, intravitreal injection of anti-VEGF agents, IVTA, laser photocoagulation, and pars plana vitrectomy. To perform this study, we enrolled the patients in whom IVTA was selected as the management option for CME, including SRD. This information has been added to the Methods section (page 3, line 2 from the bottom to page 4, line 5 from the top).